Clinical Trial
. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial Pawel Wiechno 2 , Boris Alekseev 3 , Nuria Sala 4 , Robert Jones 5 , Ivo Kocak 6 , Vincenzo Emanuele Chiuri 7 , Jacek Jassem 8 , Aude Fléchon 9 , Charles Redfern 10 , Carsten Goessl 11 , Joseph Burgents 11 , Robert Kozarski 12 , Darren Hodgson 13 , Maria Learoyd 12 , Fred Saad 14Affiliations
AffiliationsItem in Clipboard
Clinical Trial
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trialNoel Clarke et al. Lancet Oncol. 2018 Jul.
. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4. Authors Noel Clarke 1 , Pawel Wiechno 2 , Boris Alekseev 3 , Nuria Sala 4 , Robert Jones 5 , Ivo Kocak 6 , Vincenzo Emanuele Chiuri 7 , Jacek Jassem 8 , Aude Fléchon 9 , Charles Redfern 10 , Carsten Goessl 11 , Joseph Burgents 11 , Robert Kozarski 12 , Darren Hodgson 13 , Maria Learoyd 12 , Fred Saad 14 AffiliationsItem in Clipboard
AbstractBackground: Patients with metastatic castration-resistant prostate cancer and homologous recombination repair (HRR) mutations have a better response to treatment with the poly(ADP-ribose) polymerase inhibitor olaparib than patients without HRR mutations. Preclinical data suggest synergy between olaparib and androgen pathway inhibitors. We aimed to assess the efficacy of olaparib plus the androgen pathway inhibitor abiraterone in patients with metastatic castration-resistant prostate cancer regardless of HRR mutation status.
Methods: We carried out this double-blind, randomised, placebo-controlled phase 2 trial at 41 urological oncology sites in 11 countries across Europe and North America. Eligible male patients were aged 18 years or older with metastatic castration-resistant prostate cancer who had previously received docetaxel and were candidates for abiraterone treatment. Patients were excluded if they had received more than two previous lines of chemotherapy, or had previous exposure to second-generation antihormonal drugs. Patients were randomly assigned (1:1) using an interactive voice or web response system, without stratification, to receive oral olaparib 300 mg twice daily or placebo. All patients received oral abiraterone 1000 mg once daily and prednisone or prednisolone 5 mg twice daily. Patients and investigators were masked to treatment allocation. The primary endpoint was investigator-assessed radiographic progression-free survival (rPFS; based on Response Evaluation Criteria in Solid Tumors version 1.1 and Prostate Cancer Clinical Trials Working Group 2 criteria). Efficacy analyses were done in the intention-to-treat population, which included all randomly assigned patients, and safety analyses included all patients who received at least one dose of olaparib or placebo. This trial is registered with ClinicalTrials.gov, number NCT01972217, and is no longer recruiting patients.
Findings: Between Nov 25, 2014, and July 14, 2015, 171 patients were assessed for eligibility. Of those, 142 patients were randomly assigned to receive olaparib and abiraterone (n=71) or placebo and abiraterone (n=71). The clinical cutoff date for the final analysis was Sept 22, 2017. Median rPFS was 13·8 months (95% CI 10·8-20·4) with olaparib and abiraterone and 8·2 months (5·5-9·7) with placebo and abiraterone (hazard ratio [HR] 0·65, 95% CI 0·44-0·97, p=0·034). The most common grade 1-2 adverse events were nausea (26 [37%] patients in the olaparib group vs 13 [18%] patients in the placebo group), constipation (18 [25%] vs eight [11%]), and back pain (17 [24%] vs 13 [18%]). 38 (54%) of 71 patients in the olaparib and abiraterone group and 20 (28%) of 71 patients in the placebo and abiraterone group had grade 3 or worse adverse events, including anaemia (in 15 [21%] of 71 patients vs none of 71), pneumonia (four [6%] vs three [4%]), and myocardial infarction (four [6%] vs none). Serious adverse events were reported by 24 (34%) of 71 patients receiving olaparib and abiraterone (seven of which were related to treatment) and 13 (18%) of 71 patients receiving placebo and abiraterone (one of which was related to treatment). One treatment-related death (pneumonitis) occurred in the olaparib and abiraterone group.
Interpretation: Olaparib in combination with abiraterone provided clinical efficacy benefit for patients with metastatic castration-resistant prostate cancer compared with abiraterone alone. More serious adverse events were observed in patients who received olaparib and abiraterone than abiraterone alone. Our data suggest that the combination of olaparib and abiraterone might provide an additional clinical benefit to a broad population of patients with metastatic castration-resistant prostate cancer.
Funding: AstraZeneca.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articlesSaad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW. Saad F, et al. Lancet Oncol. 2022 Oct;23(10):1297-1307. doi: 10.1016/S1470-2045(22)00498-3. Epub 2022 Sep 2. Lancet Oncol. 2022. PMID: 36063830 Clinical Trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K. Beer TM, et al. Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9. Lancet Oncol. 2017. PMID: 29033099 Clinical Trial.
Perletti G, Monti E, Marras E, Cleves A, Magri V, Trinchieri A, Rennie PS. Perletti G, et al. Arch Ital Urol Androl. 2015 Jul 7;87(2):121-9. doi: 10.4081/aiua.2015.2.121. Arch Ital Urol Androl. 2015. PMID: 26150028 Review.
Zhou ZR, Liu SX, Zhang TS, Xia J, Li B. Zhou ZR, et al. Asian Pac J Cancer Prev. 2014;15(3):1313-20. doi: 10.7314/apjcp.2014.15.3.1313. Asian Pac J Cancer Prev. 2014. PMID: 24606458 Review.
Wang G, Liu Y, Liu S, Lin Y, Hu C. Wang G, et al. Int J Mol Sci. 2022 Oct 21;23(20):12647. doi: 10.3390/ijms232012647. Int J Mol Sci. 2022. PMID: 36293504 Free PMC article. Review.
Chalfant V, Riveros C, Singh P, Shukla S, Balaji N, Balaji KC. Chalfant V, et al. J Mol Med (Berl). 2023 Apr;101(4):341-349. doi: 10.1007/s00109-023-02298-4. Epub 2023 Feb 27. J Mol Med (Berl). 2023. PMID: 36843036 Review.
Feng Q, He B. Feng Q, et al. Front Oncol. 2019 Sep 4;9:858. doi: 10.3389/fonc.2019.00858. eCollection 2019. Front Oncol. 2019. PMID: 31552182 Free PMC article. Review.
Neviere Z, Coquan E, Brachet PE, Meriaux E, Bonnet I, Krieger S, Castéra L, Vaur D, Boulouard F, Leconte A, Lequesne J, Lelaidier A, Ricou A, Joly F. Neviere Z, et al. Curr Oncol. 2022 Apr 15;29(4):2776-2791. doi: 10.3390/curroncol29040226. Curr Oncol. 2022. PMID: 35448200 Free PMC article.
Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S. Yi M, et al. Exp Hematol Oncol. 2019 Nov 11;8:29. doi: 10.1186/s40164-019-0154-9. eCollection 2019. Exp Hematol Oncol. 2019. PMID: 31737426 Free PMC article. Review.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3